Many healthcare and life sciences orgs today manage multiple Cloud platforms by default. This mix of public, private and Edge Cloud architecture provides organizations with a variety of benefits, including increased flexibility. Not all…
Continue Reading
Millions of women worldwide are affected by breast cancer, a prevalent form of cancer. For approximately 8 out of 10 cases, invasive ductal carcinoma (IDC) is the most prevalent form of breast cancer. IDC…
Continue Reading
The Shift Toward an Employer-Driven Market in Healthcare TechnologyBy Mike Silverstein
Mike Silverstein is managing partner of the healthcare IT and life sciences practice of Direct Recruiters, Inc. of Solon, OH.
…
Setting up a modern healthcare technology environment spanning on-premise and multicloud locations requires a comprehensive strategy that takes time, needs to be application-based, and allows for an on-ramp to move entire ecosystems of applications.
Due…
What You Should Know:
Walgreens and Freenome form a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will combine its national footprint, patient insights, compliant recruitment technology…
Continue Reading
The 2023 annual report, titled “Mission Critical: Bringing drug discount stakeholders together so patients win,” outlines Kalderos’ vision for a new paradigm of cooperation among drug discount program stakeholders in which everyone benefits —…
Continue Reading
Technology-driven innovations are dramatically altering the way modern life sciences operate, enabling a paradigm shift from treating diseases and their symptoms to preventing and curing them.
The UK-based Galleri trial uses Artificial Intelligence (AI) based…
The following is a guest article by Steven Lazer, Global Healthcare & Life Sciences CTO, Alex Long, Head of Life Sciences Sales Strategy, and Michael Giannopoulos, Healthcare Global CISO and CTO for the Americas…
Continue Reading
What You Should Know:
Nearly three-fourths of life sciences organizations surveyed have invested in digital pathology to advance drug research and development (R&D), according to new research commissioned by Proscia®. Over half of these organizations (53%) still…
Continue Reading
When regulators speak, we listen.
Naturally risk-averse industries like the life sciences need health authority acceptance before trying new approaches and especially before committing to wholesale operational change, even if the outcome has great potential….
